miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2

Lin Zhang1, Xiaodong Liu, Haifeng Jin

  • 1State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province, China.

Cancer Letters
|January 26, 2013
PubMed

Insights

MicroRNA-206 (miR-206) is decreased in gastric cancer (GC), suppressing tumor growth by targeting cyclin D2. Restoring miR-206 offers a potential therapeutic strategy for GC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gastric cancer (GC) remains a significant global health challenge.
  • The role of microRNAs (miRNAs) in GC pathogenesis is an area of active research.
  • Understanding specific miRNA dysregulation, like miR-206, is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the expression levels of miR-206 in gastric cancer.
  • To explore the functional impact of miR-206 on gastric cancer cell proliferation in vitro and in vivo.
  • To identify potential molecular targets of miR-206 in gastric cancer.

Main Methods:

  • Real-time PCR was used to quantify miR-206 expression in GC tissues and cell lines.
  • In vitro assays assessed the effects of miR-206 restoration on GC cell growth and colony formation.
  • Cell cycle analysis was performed to determine the mechanism of growth inhibition.
  • Western blotting or similar techniques were implied for target validation (CCND2).

Main Results:

  • miR-206 expression was significantly downregulated in 30 GC samples and GC cell lines.
  • Restoration of miR-206 inhibited GC cell proliferation and colony formation.
  • miR-206 induced G0/G1 cell cycle arrest in GC cells.
  • miR-206 was found to target cyclin D2 (CCND2), contributing to proliferation suppression.

Conclusions:

  • miR-206 acts as a tumor suppressor in gastric cancer.
  • The downregulation of miR-206 contributes to GC progression.
  • miR-206 represents a potential therapeutic target for gastric cancer treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...